Related Experiment Video
Updated: May 25, 2026
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Therapy for obesity based on gastrointestinal hormones
Jonatan I Bagger1, Mikkel Christensen, Filip K Knop
1Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark.
The Review of Diabetic Studies : RDS
|January 21, 2012
Summary
Incretin-based therapies, like GLP-1 receptor agonists, show promise for treating obesity by promoting weight loss, unlike DPP-4 inhibitors which are weight neutral. This review explores intestinal peptides for new obesity treatments.
Area of Science:
- Endocrinology
- Metabolism
- Pharmacology
Background:
- Gastrointestinal peptide hormones regulate nutrient metabolism.
- Incretins enhance insulin secretion, leading to incretin-based therapies for type 2 diabetes.
- These therapies offer positive outcomes for body weight, unlike other antidiabetic treatments.
Purpose of the Study:
- To review the effects of incretin-based therapies on obesity.
- To provide an overview of intestinal peptides with potential weight-reducing properties.
- To explore new potential treatments for obesity.
Main Methods:
- Review of current literature on incretin-based therapies.
- Analysis of physiological effects of intestinal peptides.
- Discussion of therapeutic applications in obesity treatment.
Main Results:
- GLP-1 receptor agonists cause significant weight loss in overweight patients.
- Dipeptidyl peptidase 4 (DPP-4) inhibitors are weight neutral.
- Increased interest in intestinal peptides for weight management.
Conclusions:
- Incretin-based therapies, particularly GLP-1 receptor agonists, are effective for weight loss in obesity.
- Further research into intestinal peptides may yield novel obesity treatments.
- The study highlights the potential of targeting gut hormones for metabolic health.
Related Concept Videos
01:40Hormonal Regulation
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Regulation of the Digestive System
Digestive activity regulation hinges on three primary components. Activation is prompted by a multitude of mechanical and chemical indicators, primarily detected by receptors within the stomach and intestines' walls. These receptors predominantly respond to factors such as mechanical stretching of the organ walls, changes in pH and osmolarity, and the presence of digesting materials and their by-products.
The effectors in this regulation system are glands and smooth muscles. Activation of these...
The effectors in this regulation system are glands and smooth muscles. Activation of these...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:25Hormones Secreted by the Stomach
Enteroendocrine cells, accounting for only 1% of stomach epithelial cells, play a significant role in digestion and are classified by their digestive hormone secretions.
Each of these hormones secreted by different enteroendocrine cells plays a unique role in digestion. Here are a few examples:
Each of these hormones secreted by different enteroendocrine cells plays a unique role in digestion. Here are a few examples: